ArticlePatient preference and adherence2025
Medication Adherence to Semaglutide versus Empagliflozin in Adults with Type 2 Diabetes: A Retrospective Observational Study in Saudi Arabia.
Article in Patient preference and adherence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rates of, Reasons for, and Reactions to Discontinuation of GLP-1 Receptor Agonists: A Narrative Review.Diabetes, obesity & metabolism · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are widely prescribed, yet medication adherence varies. This study evaluated real-world adherence and persistence to semaglutide and empagliflozin among adults with T2D and assessed the associations between adherence and clinical outcomes. Patients and Methods: A retrospective observational study was performed using electronic health records and pharmacy dispensing data from a military hospital in Tabuk, Saudi Arabia, between July 1, 2023 and June 30, 2024. Adults with T2D (≥18 years old) prescribed semaglutide or empagliflozin were included. Medication adherence was quantified using proportion of days covered (PDC). Persistence was defined by absence of treatment gap ≥60 days. Associations between adherence and patient characteristics, and clinical out-comes, were examined. Results: Among 5087 patients (mean age 57.9 ± 12.3 years, mean T2D duration 10.3 ± 7.6 years), 4020 received empagliflozin and 1067 initiated semaglutide. Adherence (PDC ≥ 80%) was observed in 57.7% of semaglutide and 60% of empagliflozin users. Persistence was lower 40% (semaglutide) and 45% (empagliflozin) met the criteria. Sociodemographic variables were not significant predictors of medication adherence. Conclusion: Medication adherence and persistence to both semaglutide once-weekly injection and oral empagliflozin were suboptimal among T2D patients. Adherent patients to both medications experienced a significant improvement in glycemic control. Targeted strategies are needed to enhance patient motivation for consistent medication use and timely refills.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.